The findings were presented Wednesday, Oct. 14, during TCT Connect 2020. 

The BRACE CORONA trial focused on the safety of taking angiotensin-converting enzyme inhibitors and angiotensin receptor blockers when hospitalized with COVID-19.

The EMPEROR-Reduced trial included data from more than 3,700 adult patients with HF and a left ventricular ejection fraction of 40% or less.

Results of the trial, which included more than 11,000 patients, were published in the New England Journal of Medicine.

Researchers tracked statin use among patients with peripheral artery disease, cerebrovascular disease and coronary heart disease.

Tafamidis received FDA approval in May 2019 for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). It has a list price of $225,000 per year.

Machine learning is playing a key role in predicting all major forms of drug cardiotoxicity, potentially helping reduce late-stage clinical trial failures.

A 92.6% reduction in the list price of tafamidis—an effective but ultimately unaffordable drug designed to treat transthyretin amyloid cardiomyopathy—would be required to make the medication accessible to the average heart patient, researchers reported in Circulation Feb. 12.